A Kinetic Study On Murine Myeloid Leukaemia by Tanaka, T. et al.
138
A KINETIC STUDY ON MURINE MYELOID LEUKAEMIA
T. TANAKA*, A. W. CRAIG AND L. G. LAJTHA
Front the Paterson Laboratories, Christie Hospital and Holt Radium Institute,
Manchester 20
Received for publication November 5, 1969
SUMMARY.-A kinetic study was made on murine myeloid leukaemia, using
the myeloid leukaemia colony in the spleen as a model system. The number of
myeloid leukaemia colony-forming units (MLCFU) recoverable from the bone
marrow, spleen and liver increased exponentially as a function of time from day
1 up to day 9, after the initial lag period of 12-24 hours. The f-values were
estimated to be about 67 per cent in the above 3 organs. After day 10, the
number of MLCFU declined in these organs. The myeloid leukaemia was
sensitive to cyclophosphamide and chlorambucil, as determined by the slopes
of the survival curves obtained for MLCFU. Finally, an entity of the mixed type
in the myeloid leukaemia colony was described.
SINCE Till and McCulloch (1961) developed the spleen colony technique for
quantitative assay of the normal haemopoietic cells, a considerable number of
papers has appeared investigating tumour cell populations, mainly lymphoma or
lymphocytic leukaemia (Bruce and van der Gaag, 1963; Wodinsky et al., 1967a),
erythroleukaemia (Axelrad and Steeves, 1964; Pluznik and Sachs, 1964) and
plasma cell tumour (Bergsagel and Valeriote, 1968). The use of these model
systems is being extended further to investigate the therapeutic (Bruce et al.,
1966; Wodinsky et al., 1967b; Vadlamudi et al., 1968; Steeves et al., 1968), genetic
(Odaka and Yamamoto, 1965), haematological (Pluznik et al., 1966) or immuno-
logical (Steeves, 1968) aspects of leukaemia. In this paper, we report growth
characteristics of the myeloid leukaemia colony in the spleen.
MATERIALS AND METHODS
MIice.-Mice used were RFM/Un strain which came from the Biology Division,
Oak Ridge National Laboratory, Tennessee, U.S.A., and RF/J strain from
Okayama University Medical School, Okayama, Japan, and have been maintained
by brother and sister matings. The RFM/Un strain were used as donors with
transplanted myeloidleukaemiaandtheRF/Jstrainas recipients forradiobiological
assay. At the time of the experiments they were 3-4 months old and 25-30 g.
in average body weight.
Leukaemia line. The RFM/Un mice bearing radiation-induced myeloid
leukaemia were transferred to this laboratory from the Oak Ridge National
laboratory in 1965. This leukaemic cell line has been passaged at 7-10 day
intervals by intravenous injections of 105 to 106 leukaemic spleen cells in sus-
pensions.
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Preparation of cell suspensions. Spleen cell suspensions from mice with ad-
vanced leukaemia were injected into groups of donor mice, each animal being
given about 105 leukaemia cells (Fig. 1). These mice were killed daily from day 1
to 12. For colony assay in the bone marrow, appropriate dilutions of marrow cell
suspensions were injected into total-body irradiated (900 rad) recipient mice.
The recipients were then killed 9 days after irradiation and injections. An
attempt was also made to obtain the growth pattern of myeloid leukaemia colony
formers in the spleen during the early leukaemic stage, i.e. up to day 5. The
donors were first irradiated with 700rad. Afterwards, spleen cell suspensions
from mice with the advanced leukaemia were injected into them. These mice
were killed at intervals from 2 hours up to 9 days after irradiation and injections.
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Fi'C. 1.-The exlerimental scheme of grafting technique applied to murine leukaemia.
(After day 9, the majority of these irradiated and leukaemic cell-iinjected mice
became moribund and further study on the very advanced stage was not feasible.)
Marrow cell suspensions from the donors were prepared and injected into irradiated
recipients, as described before.
For colony assay in the spleen, appropriate dilutions of spleen cell suspensions
obtained from non-irradiated or irradiated (700 rad) and transplanted donors were
injected into irradiated (900 rad) recipients, in place of bone marrow cells. A
liver homogenate was prepared by mincing the liver from the advanced leukaemic
mice, passing the finely minced tissue suspended in Hanks' solution through fine
steel grids of 2 different pore sizes, allowing coarse tissue fragments to settle for
5 minutes, and finally suspending a part of this material in a known amount of
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Hanks' solution. The actual number of intact, non-hepatic, nucleated cells was
obtained with a haemocytometer.
Chemotherapeutic agents and cell survivals.-Normal mice were treated with a
single injection of chemotherapeutic agent intraperitoneally, and were killed
24 hours later. Marrow cell suspensions of appropriate concentrations were then
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FIG. 2. The number of colony-forming units recoverable from the femoral marrow at various
times after injection of leukaemic cells. The curve A was obtained from the donor mice
non-irradiated and leukaemic cell-injected. The curve B was obtained from the donor
mice irradiated (700 rad) and leukaemic cell-injected. The points show the mean and the
bars the standard error for a group of, at least, 12 mice.
prepared from the treated mice and injected into groups of total body-irradiated
(900 rad) recipients. Nine days later, the mice were killed for colony assay. To
assess the sensitivity of transplanted myeloid leukaemia cells to the agents,
approximately 106 to 107 spleen cells in suspensions from the advanced leukaemic
mice were inoculated into normal syngeneic mice, 4-5 days before drug therapy.
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Using this system, a surviving fraction of drug-treated normal haemopoietic
colony-forming units (NHCFU) and myeloid leukaemia colony-forming units
(MLCFU) was calculated from the numbers of NHCFU and MLCFU in the un-
treated mice.
10
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FIG. 3.--The number ofcolony-forming units recoverable from the spleen at various times after
injection of leukaemic cells. The curve A was obtained from the donor mice non-irradiated
and loukaemic cell-injected. The curve B was obtained from the donor mice irradiated
(700 rad) and leukaemic cell-injected.
RESULTS
The nuniber of MLCFU recoverable from the bone marrow (femur) increased
exponentially as a function oftime from day 5 to 9 with a doubling time of about
14-15 hours (Fig. 2). Afterwards, the number started to decline. In view ofthe
constancy of the number of CFU up to day 5, it was assumed that these CFU
were mainly derived from NHCFU (Tanaka and Lajtha, 1969). Using the
donors total body-irradiated (700 rad) and leukaemic cell-injected, MLCFU
141T. TANAKA, A. W. CRAIG AND L. G. LAJTHA
continued to grow at a constant rate from day 1 up to day 9, after the initial lag
period of 12-24 hours (Fig. 2). The growth pattern of MLCFU per spleen and
liver was virtually the same as seen in the bone marrow (Fig. 3 and 4). In the
latter 2 organs, the number of MLCFU, instead of falling as in the bone marrow,
gradually slowed down after day 10. In contrast to the observation made in the
marrow and spleen, the initial lag phase was not demonstrable in the liver.
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FIG. 4.-The number of colony-forming units recoverable from the liver at various
times after injection of leukaemic cells.
MLCFU per liver reached a factor of 2-5-3 ofthat per spleen in the advanced stage
of day 10 onwards. The f-value, i.e. the fraction of CFU recoverable from an
organ (Siminovitch et al., 1963), was estimated to be about 67 per cent in the above
three major organs (Table I).
With cyclophosphamide and chlorambucil (kindly supplied by Dr. J. M. Frisch,
the Wellcome Foundation Ltd., London), a significant difference in sensitivity was
noticed as determined by the slopes of the curves obtained for NHCFU and
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MLCFU (Fig. 5a and b). In contrast, graded doses of Myleran or dibromo-
mamiitol produced little difference in cell survivals (Fig. 6a and b).
Great care was taken to enucleate discrete colonies. In spite ofthe precaution,
there was a small percentage (about 3-4 per cent) of " mixed type " of myeloid
leukaemia colony (Fig. 7). This consisted of myeloid leukaemia cells and normo-
blasts in approximately equal proportions. (Under these circumstances, the
mixed type of colony did not result from crowding of colonies.)
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FIG. 5a.--Sensitivity of normal haemopoietic (NHCFU) and myeloid (MLCFU) leukaemia
colonies to cyclophosphamide.
The points show the mean and the bars the standard error for a group of, at least, 12 mice.
DISCUSSION
The growth pattern of leukaemic cells, reflected by numbers of MLCFU
recoverable from the bone marrow (femur), spleen and liver can be divided into
three phases (Fig. 8). The lag and exponential growth phases may be divided into
two stages distinguishable from the clinical view-point as the preleukaemic and
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leukaemic stages. In the preleukaemic stage no organomegaly or leukocytosis is
detected, up to about day 5. In the leukaemic stage, leukocyte counts and spleen
weights will increase in a parallel fashion (unpublished observation), and leukaemia
colonies become predominant in the spleen (up to about day 9). Finally, in the
advanced stage, some mice start to die with leukaemia and the growth curve of
MLCFU will slow down.
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Fic. 5b. Sensitivity of normal haemopoietic (NHCFU) and myeloid (MLCFU) leukaemia
colonies to chlorambucil.
The.points show the mean and the bars the standard error for a group of, at least, 12 mice.
The lag phase (approximately 12-24 hours) compares with 24-48 hours in
L1210 lymphocytic leukaemia (Wodinsky et al., 1967a) and 48 hours (McCulloch
and Till, 1964) to 72 hours (Kretchmar and Conover, 1968) in normal haemopoietic
colonies. No lag phase is detectable in AKR lymphoma (Bruce and Meeker, 1964).
The f-value studied on AKR lymphoma (Bruce and Meeker, 1964) amounts to
13 per cent (Table I). The discrepancy of the f-values (67 vs. 13 per cent in
145146 T. TANAKA-, A. W. CRAIG AND L. G. LAJTHA
myeloid leukaemia and AKR lymphoma, respectively) is unquestionably large.
This may be due to a difference in pattern of leukaemic infiltrations between
lymphocytic and myeloid leukaemia. In the latter, the major leukaemic features
are confined to the liver, spleen and bone marrow.
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FIG. 6.-Sensitivity of normal haemopoietic (NHCFU) and myeloid (MLCFU) leukaemia
colonies
(a) to Myleran
(b) to dibromommanitol.
The exponential growth phase was followed by a growth inhibition in the
advanced stage, which contrasts to the observation in AKR lymphoma (Bruce
and Meeker, 1964) and L1210 leukaemia (Wodinsky et al., 1967a). The growth
inhibition may be due to an acute cellular depletion commonly found in the bone
EXPLANATION OF PLATE
FIG. 7.-The mixed type of myeloid leukaemia colony, showing normoblasts and leukaemic
myeloid cells in approximately equal proportions. May-Giemsa. x 320.BRITISH JOURNAL OF CANCER.
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marrow and due to leukaemia cells in the spleen and liver which start to prolong
their cell cycle time or are held up in cell cycle (Lajtha and Gilbert, 1967). This
might be significant, firstly because assessment of chemotherapeutic agents is
sometimes based on the results obtained merely from the exponential growth in
murine leukaemia system such as the effect ofBCNU on L1210 leukaemia (Skipper
et al., 1964); secondly because ofthe enormous capacity ofthe liver for proliferation
ofleukaemic cells in the advanced stage, it may be difficult to eradicate malignant
cells completely from infiltrated organs with therapeutic drugs. The second
point has been apparently experienced byValeriote etal. (1968) in AKR lymphoma.
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FIG. 8.-A schematic presentation of the growth pattern of myeloid leukaemia colony
compared with the leukaemic stages.
In accord with the observation on AKR lymphoma colony by Bruce et al.
(1966), the " saturation values " with increasing dosage were not obtained by
using cyclophosphamide or chlorambucil on myeloid leukaemia colony. As they
suggested, cells appear to be sensitive to these agents throughout or for the most
part of their cell cycle, and the difference in sensitivity between normal haemo-
poietic and leukaemic cells to the drugs may be a consequence of cell proliferation
(14-15 hours for myeloid leukaemia colony as opposed to 20-25 hours for normal
haemopoietic colony by McCulloch and Till, 1964).
Though the pathogenesis of the mixed type of myeloid leukaemia colony
needs to be studied further, it may elucidate to a certain extent the problem of
uni- or multi-potentiality of the stem cells. As noticed in this and previous
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(Tanaka and Lajtha, 1969) studies, there is a fundamental difference between
lymphocytic leukaemia or lymphoma and myeloid leukaemic colonies. This
point was confirmed by a quantitative difference in response to, e.g. cyclophos-
phamide, not only between NHCFU and MLCFU but between MLCFU and
lymphocytic leukaemia colony-forming units (unpublished observation). The
existence of an advanced leukaemic stage, corresponding to an over-growth phase
of myeloid leukaemia cell population is possibly comparable to the advanced
situation in the human disease. In spite of its short duration in mice, its closer
study, especially regarding changing growth fraction, will require further investi-
gation.
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